Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 19, 2025
Product Development
Tempus aims for precision in complexity
With clinical records, patient samples and images in the millions, the diagnostics and data company is betting precision medicine can go multimodal
BioCentury | Mar 13, 2025
Product Development
Managing Novartis’ pipeline in an era of fast innovation: Vas Narasimhan in conversation
How the pharma CEO views precision medicine, rising challenges in radioligand therapy, and the CAR T immune reset opportunity
BioCentury | Sep 12, 2024
Product Development
Clinical Report: AstraZeneca, Daiichi turn to precision medicine after OS miss for Dato-DXd
Plus: Results from Relay, Centessa, Viridian, Amgen and more
BioCentury | Sep 6, 2024
Distillery Therapeutics
CAR T cells targeting FGFR4 and B7-H3 for pediatric rhabdomyosarcoma
BioCentury | Aug 14, 2024
Deals
Deals Report: Pair of Merck deals in APAC region; Recursion and Exscientia merging
Plus: Denmark-based Pharmacosmos buys G1, obtaining myelosuppression drug
BioCentury | Jun 18, 2024
Product Development
Tumor cell surface targets off the beaten path
Beyond the headlines at ASCO and AACR were a set of less traveled cancer targets, including neuronal proteins hijacked by solid tumors
BioCentury | Jun 5, 2024
Data Byte
15 PDUFA dates on FDA’s roster in June
Upcoming decisions include HER3 ADC from Daiichi-Merck and full approval for Sarepta’s DMD gene therapy
BioCentury | May 14, 2024
Data Byte
The diverse modalities targeting B7-H3
ADCs against the target have raised safety concerns, but companies are hitting B7-H3 with other modalities
BioCentury | May 14, 2024
Product Development
Clinical Report: MacroGenics faces ADC safety concerns
Plus data from CytomX, Merck, Regeneron and more
BioCentury | Apr 12, 2024
Product Development
Cambrian explosion of ADCs at AACR24
Conference showcases six emerging ADC payload types, and trends in antigen pairs for bispecific ADCs
Items per page:
1 - 10 of 76